BioSpace News Archive

Lannett Company, Inc. (NYSE: LCI) today announced that it has begun marketing Chlorpromazine Hydrochloride Tablets, USP, 10 mg, 25 mg, 50 mg, 100 mg and 200 mg.

IN8bio, Inc., a clinical-stage biotechnology company focused on developing innovative allogeneic, autologous and genetically modified gamma-delta T cell therapies for the treatment of cancers (“IN8bio” or the “Company”), today announced the appointment of Patrick McCall, CPA, as Chief Financial Officer. “We welcome Patrick to IN8bio and look forward to his contributions to the company,” said William Ho, Chief Executive Officer of IN8bio. “Patrick

- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that it will issue financial results for its fiscal quarter ended December 31, 2020 on Thursday, February 11, 2021 at 4:30 pm ET

Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced today the peer-reviewed journal Psychiatry Research has published a new analysis showing the combinatorial approach available in the GeneSight® Psychotropic test is better than single-gene testing at predicting patient outcomes and medication blood levels.

OliX Pharmaceuticals, Inc . (KOSDAQ: 226950), a leading developer of RNAi therapeutics, has announced the establishment of mCureX Therapeutics, Inc., a subsidiary focused on the research and development of messenger RNA (mRNA) vaccines and therapeutics.

Pre-IND Meeting Written Response from FDA Provides Guidance on Product Development and Clinical Testing Protocol Intradermal Test is Designed to Measure SARS-CoV-2 Specific Delayed Type Hypersensitivity (DTH), the Classic Method of Measuring T Cell Immunity to Tuberculosis and Other Pathogens Multiple Potential Uses Include Functional Measure of T Cell Immunity to SARS-CoV-2; Aid to COVID-19 Diagnosis and Public Health Surveillance; Endpoint for COVID-19 Vaccine Trials

SmartBreast Corporation (SmartBreast™), a privately held company focused on breast cancer screening and diagnosis, announced today that it has acquired the Discovery NM750b Molecular Breast Imaging (MBI) assets from GE Healthcare,

Q-State Biosciences , a technology-derived medicines company, today announced that it has achieved the primary program completion milestone in its research collaboration with Chamishi Therapeutics.

- Business combination transaction with FS Development Corp., a special purpose acquisition company sponsored by Foresite Capital, completed on February 5, 2021 – - Combined company renamed Gemini Therapeutics, Inc. – - Common stock commences trading today on the Nasdaq Global Market under ticker symbol “GMTX” –

FairJourney Biologics (FJB) and IONTAS, leaders in the discovery and optimization of antibodies, have today announced the launch of a new protein sciences division, Flow Eighteen38.